Official UK procurement notice
NHS Framework Agreement for the supply of licenced Human Albumin Solution & Normal and Anti-D Immunoglobulins
Authority: NHS England (Central government)
What is being bought
Published requirement descriptionThis market engagement relates to the NHS Framework Agreement for the supply of licenced Human Albumin Solution & Normal and Anti-D Immunoglobulins. The framework is anticipated to commence on 1 January 2025 for a period of 36 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. Total maximum framework agreement including extension options will be no more than 48 months. The purpose of the PIN is to engage with the supply market on the procurement approach and to understand market and supplier capacities prior to the Invitation to Tender.
CPV: Immunoglobulins
The lotProcurement structure
single lot · no lot value publishedLot #11-7Planned
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
- “NHS Framework Agreement for the supply of licenced Human Albumin…” is a framework: the contest is a place on its panel, not a single contract.
Procedure terms & legal framework
From the official record · publisher note attached- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Past planning notice
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use this agreement
- Not stated in the notice; call-off rights may be limited to the establishing authority
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 13 Mar 2024, 13:47 GMT
- Last source update
- 13 Mar 2024, 13:47 GMT
- Authority reference
CM/PHS/23/5703- FTS notice number
2024/S 000-008035- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-044823Find a Tender
Publisher note: This market engagement relates to the NHS Framework Agreement for the supply of licenced Human Albumin Solution & Normal and Anti-D Immunoglobulins. The framework is anticipated to commence on 1 January 2025 for a period of 36 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. Total maximum framework agreement including extension options will be no more than 48 months. <br/><br/>The purpose of the PIN is to engage with the supply market on the procurement approach and to understand market and supplier capacities prior to the Invitation to Tender. <br/><br/>The market engagement documents will be made available during March for unrestricted and full direct access, free of charge, at http://health.atamis.co.uk under project reference C228466.<br/><br/>Please be aware the NHSE principal address has changed to Wellington House 133-155 Waterloo Road London SE1 8UG
How it was run
Official noticeTender documents are also served through a separate tool: https://health-family.force.com/s/Welcome ↗
- Appointment period ends
- —
Timeline
13 Mar 2024 → 28 May 2024 · 2 dates- Notice published13 Mar 2024, 13:47 GMT
- Tender notice expected28 May 2024, 00:00 BST
Commercial outcome & contract awards
Pipeline notice- Awards (0)
- No award published
- Contracts (0)
- No contract published
- Bid statistics
- No aggregate bid statistics published
Contracting authority & participating public bodies
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.